YHYunlong Huang

Yunlong Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yunlong Huang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • LncRNA PTPRG‐AS1 facilitates glycolysis and stemness properties of esophageal squamous cell carcinoma cells through miR‐599/PDK1 axis

    by Kaiming Wu, Ziao Wang, Yunlong Huang, Long Yao, Ningning Kang, Wei Ge, Renquan Zhang, Wei He

    Background and Aim: Esophageal squamous cell carcinoma (ESCC) is the most significant subtype of esophageal cancer featured with high occurrence. Long noncoding RNAs (lncRNAs) have been proved to modulate the biological properties of cancer cells, including cell proliferation, invasion, migration, and apoptosis. LncRNA protein tyrosine phosphatase receptor type G‐antisense RNA 1 (PTPRG‐AS1) has been reported to play as an oncogene in diverse cancers. However, the detailed function PTPRG‐AS1 may exert in ESCC is unclear.Methods: PTPRG‐AS1 expression in ESCC cells was investigated via quantitative reverse transcription real‐time polymerase chain reaction (RT‐qPCR). The effects of PTPRG‐AS1 on ESCC cell proliferation, migration, glycolysis, and stemness were verified through functional assays. Mechanism assays including RIP assay, RNA pull down assay, and luciferase reporter assays were performed to verify the molecular mechanism of PTPRG‐AS1.Results: PTPRG‐AS1 silencing hindered the proliferation, migration, glycolysis and stemness of ESCC cells. PTPRG‐AS1 regulated pyruvate dehydrogenase kinase 1 (PDK1) expression via sponging miR‐599. The PTPRG‐AS1/miR‐599/PDK1 axis was further verified to aggravate the progression of ESCC cells.Conclusion: PTPRG‐AS1 sponged miR‐599 to up‐regulate PDK1 expression, thereby promoting the proliferation and migration as well as glycolysis and stemness properties of ESCC cells.


  • Open Access

    Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis

    by Long Yao, Mengke Liu, Yunlong Huang, Kaiming Wu, Xin Huang, Yuan Zhao, Wei He, Renquan Zhang

    Background. Antidiabetic medications (ADMs) can alter the risk of different types of cancer, but the relationship between lung cancer incidence and metformin remains controversial. Our aim was to quantitatively estimate the relationship between incidences of lung cancer and metformin in patients with diabetes in this meta-analysis. Methods. We performed a search in PubMed, Embase, ISI Web of Science, and Cochrane Library until September 20, 2017. The odds ratio (OR), relative risk (RR) or hazard ratio (HR), and 95% confidence interval (95% CI) were estimated using the random-effect model. The Newcastle-Ottawa Scale (NOS) was used to assess the study quality. Results. A total of 13 studies (10 cohort studies and 3 case-control studies) were included in the meta-analysis. Compared to nonmetformin users, metformin probably decreased lung cancer incidence in diabetic patients (RR=0.89; 95% CI, 0.83-0.96; P=0.002) with significant heterogeneity (Q=35.47, I2=66%, P=0.0004). Subgroup analysis showed that cohort studies (RR=0.91; 95% CI, 0.85-0.98; P=0.008), location in Europe (RR=0.90; 95% CI, 0.86-0.94; P<0.0001), the control drug of the sulfonylurea group (RR=0.91; 95% CI, 0.86-0.96; P=0.001), and adjusting for smoking (RR=0.86; 95% CI, 0.75-1.00; P=0.05) may be related to lower lung cancer risk. No significant publication bias was detected using a funnel plot. Conclusion. Metformin use was related to a lower lung cancer risk in diabetic patients compared to nonusers, but this result was retrieved from observational studies and our findings need more well-designed RCTs to confirm the association.